Background

This project aims to identify a profile of amyloid β-peptides in cerebrospinal fluid that is specific for CAA. If we manage to establish a CAA-specific profile of amyloid β peptide, this offers new possibilities for (early) diagnosis of CAA and monitoring the progression of the disease.

lees meer

Background

This project aims to identify a profile of amyloid β-peptides in cerebrospinal fluid that is specific for CAA. If we manage to establish a CAA-specific profile of amyloid β peptide, this offers new possibilities for (early) diagnosis of CAA and monitoring the progression of the disease.


SCALA: an amyloid beta profile Specific for Cerebral AmyLoid Angiopathy.

Aim

To identify a profile of amyloid β/amyloid β precursor (APP) peptides in the CSF that is specific for CAA. Identification of this specific amyloid β/APP profile will provide a novel diagnostic tool that allows (early) diagnosis of CAA during life and allows monitoring of the disease.

Methods

We have developed a new and sensitive targeted proteomic method to profile >120 endogenous CSF amyloid β/ peptides within a single analysis.

read more

Methods

We have developed a new and sensitive targeted proteomic method to profile >120 endogenous CSF amyloid β/ peptides within a single analysis,

This was based on a highly sensitive immunoprecipitation (IP) procedure followed by high resolution mass spectrometry (MS) analysis or matrix assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI TOF/TOF). Since mass spectrometry is not suitable for large-scale biomarkers studies, we will develop ELISAs for the CAA-specific amyloid β/APP peptides.

Duration of the project

The duration of the project is 2 years, start in 2019.

Partners

  • University of Gothenburg in Sweden

Funding

This project is funded by the Canadian Weston Brain Institute.